Meeting Thu, 04/20/2023 - 12:00 Drug Utilization Review Board Meeting Information

Date
Media
Edit Implementation Schedule April 2023
New Drugs and Edits with no annual changes April 2023
PDL Announcement 04-20-23
Conduent Reports April 2023
Missouri Board of Pharmacy Continuing Education April 2023
MO Pharmacy Advisory Board Slides April 2023
Agenda
DUR Agenda April 2023
Minutes
DUR Minutes April 2023
Criteria
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Acne and Rosacea – Select Topical Agents Step Therapy Edit April 2023
Fabry Disease April 2023
Givlaari April 2023
Imcivree April 2023
Isturisa April 2023
Megestrol Acetate April 2023
Nulibry April 2023
Oxervate April 2023
Oxlumo April 2023
Scenesse April 2023
Sickle Cell Disease April 2023
Spravato April 2023
Systemic Antifungals April 2023
Tavneos April 2023
Voxzogo April 2023
Zulresso April 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Hemgenix April 2023
Tzield April 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents, Topical April 2023
Androgenic Agents April 2023
Antibiotics, Inhaled April 2023
Anticholinergics, LABA Combo, Short Acting and Combo Inhaled April 2023
Antihistamines and Antihistamine/Decongestant Combinations, 2nd Generation April 2023
Antihistamines, Intranasal April 2023
Antiparasitics, Topical April 2023
Antivirals, Herpes Oral April 2023
Benzoyl Peroxide/Antibiotic Combinations April 2023
Beta Adrenergic Agents, Nebulized April 2023
Beta Adrenergic Agents, Short Acting April 2023
Corticosteroids, Ophthalmic “Soft” April 2023
Corticosteroids, Oral Inhaled April 2023
Corticosteroids, Topical April 2023
Cough and Cold Preparations April 2023
Fluoroquinolones, Ophthalmic April 2023
Fluoroquinolones, Otic April 2023
Hepatitis C Agents April 2023
Leukotriene Receptor Modifiers April 2023
Mast Cell Stabilizers, Ophthalmic April 2023
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Ophthalmic April 2023
Pancreatic Enzyme Agents April 2023
Retinoids, Topical April 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticholinergics, LABAs/ICS Combinations and PDE4 Inhibitors April 2023
Anticholinergics, Long Acting Inhaled April 2023
Antifungals, Oral April 2023
Antihistamines, Ophthalmic April 2023
Antivirals, Topical April 2023
Beta Adrenergic Agents, Long Acting April 2023
Corticosteroids & Rhinitis Agents, Intranasal April 2023
Epinephrine Agents, Self-Injectable April 2023
Glaucoma Agents April 2023
Inflammatory Bowel Disease Agents, Oral April 2023
Inflammatory Bowel Disease Agents, Rectal April 2023
Page
Drug Utilization Review Board Meeting Information